Salarius Pharmaceuticals Inc. has announced an update to its merger agreement with Decoy Therapeutics Inc. The company has entered into a Fourth Amendment to the Agreement and Plan of Merger to modify the conversion terms of its Series A and Series B Non-Voting Convertible Preferred Stock. This amendment aims to encourage consent and conversion by holders of certain convertible and non-convertible notes of Decoy. Key modifications include the removal of a $2 million threshold requirement for triggering a "subsequent financing," a change in the conversion price adjustment calculation to reflect the actual per share offering price in any future financing, and the elimination of the one-year limitation on adjustments to the conversion ratio. The adjustment will now apply until stockholder approval is obtained and applicable Nasdaq initial listing standards are met.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。